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Abstract
To date, no immunization of humans or animals has elicited broadly neutralizing sera able to prevent HIV-1 transmission;
however, elicitation of broad and potent heavy chain only antibodies (HCAb) has previously been reported in llamas. In this
study, the anti-HIV immune responses in immunized llamas were studied via deep sequencing analysis using broadly
neutralizing monoclonal HCAbs as a guides. Distinct neutralizing antibody lineages were identified in each animal, including
two defined by novel antibodies (as variable regions called VHH) identified by robotic screening of over 6000 clones. The
combined application of five VHH against viruses from clades A, B, C and CRF_AG resulted in neutralization as potent as any
of the VHH individually and a predicted 100% coverage with a median IC50 of 0.17 mg/ml for the panel of 60 viruses tested.
Molecular analysis of the VHH repertoires of two sets of immunized animals showed that each neutralizing lineage was only
observed following immunization, demonstrating that they were elicited de novo. Our results show that immunization can
induce potent and broadly neutralizing antibodies in llamas with features similar to human antibodies and provide a
framework to analyze the effectiveness of immunization protocols.
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Introduction
HIV transmission remains a huge global public health problem
(www.UNAIDS.org). To reduce spread of the virus new preven-
tion methods are being developed based on recent advances in the
molecular virology of HIV. In addition to the expanded use of
ARVs in new modalities such as pre-exposure prophylaxis and
microbicides [1], this includes commensal microbicides [2], gene
therapies [3,4] and vaccines [5,6,7]. Recent major advances in
identifying broad and potent HIV neutralizing monoclonal
antibodies (mAb) provide invaluable reagents for the development
of these strategies to prevent HIV infection. It is well-established
that passive infusion of neutralizing mAb can prevent SHIV
infection [8,9,10,11,12,13] and recently it was shown that a mAb
can treat infection in non-human primate (NHP) models [14].
This combined with the success of antibody-inducing vaccines
against other pathogens suggested that a vaccine that can induce
neutralizing antibodies at sufficient titers could protect against
HIV [15]. While viral escape has not been observed in the NHP
models of immunoprophylaxis described above, virus can evolve in
response to neutralizing antibodies in HIV-positive patients
[16,17] and early studies showed escape of patient virus from
passive antibody-mediated protection when a single mAb was used
[18]. However, recent in vitro work has shown increased
neutralization coverage can be achieved by combining the newly
identified broadly neutralizing mAb [19,20]. These findings
highlight the need to (a) induce multiple neutralizing antibody
lineages for a protective antibody-based vaccine and (b) the
potential need to use combinations of purified mAb in therapeutic
or prophylactic settings.
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To date, immunizations in human and animal models have
yielded antibodies with only limited ability to neutralize HIV
[21,22,23,24], except llama heavy chain only antibodies (HCAbs)
isolated as individual variable regions (VHH) [25]. Previously, we
isolated the VHH J3 from a llama immunized with HIV envelope
glycoprotein (Env) in the form of trimeric recombinant gp140
subunits and found it neutralized 96 of 100 HIV-1 strains by
targeting the CD4-binding site (CD4bs) [26]. Llamas, along with
other camelids have HCAb in additional to conventional heavy
and light chain antibodies, [27]. The VHH is the total antigen
binding domain or active site of these single-headed immunglo-
bulins (IgG) and llama antibodies have been studied in this single
domain form due to the dual advantages of bacterial/yeast
expression and their high levels of thermal and pH stability [28].
As stable single domains, VHH have advantages for use in
microbicides both in terms of gels [28] and protection by
commensal bacteria [29].
In this study, we identified three new broadly neutralizing
VHH, which bind to the CD4-binding site of the Env subunit
gp120 and bind the molecular probe used to isolate VRC01. Deep
sequencing of the VHH phage libraries generated from a set of
llamas, which received two different immunization protocols,
showed that the new VHH and the previously described anti-HIV
VHH J3 [26] were induced by immunization (Table 1). As such
the HIV llama vaccination model is robust and reproducible and
demonstrates the potential of a mammalian immune system to
produce broadly HIV neutralizing antibodies in response to
immunization. We also demonstrate that multiple broadly
neutralizing antibody lineages can be raised against HIV in the
llama HCAb model and that, when combined as purified VHH,
they provide enhanced breadth and potency of neutralization.
Results
Identification of novel HIV neutralizing VHH from
immunized llamas
Two llamas (Lama glama) (designated Llama 1 and Llama 3)
were immunized via intramuscular injection of DNA encoding R2
and 96ZM651.02 gp160, and twice more with this DNA in
combination with virus-like particles (VLP) bearing R2 and
96ZM651.02 gp145 protein (Table S1 in S1 Text). Sera taken
one week after the last immunization (t = 54) showed measurable
binding to homologous gp140 proteins in ELISA but no HIV
neutralization activity in the TZM-bl assay (Figure S1 in S1 Text).
Both llamas were subsequently immunized a further four times
with soluble recombinant gp140 proteins again from R2 and
96ZM651.02 HIV strains. In contrast to non-neutralizing response
at t = 54, post immune sera taken from both llamas one week after
the final protein immunization (t = 174) neutralized HIV strains
from clades A, B and C at 50% inhibitory dilutions (ID50) ranging
from 1:8 up to 1:200 (Figure S1 in S1 Text). While the potency of
these responses is modest, the breadth of activity included
‘difficult-to–neutralize’ strains (categorized as tier 2, where tier 1
is easiest and tier 3 is most difficult to neutralize) [30] from clades
A and C, and titers of.1: 100 were seen for both llamas against
the homologous strain 96ZM651.02. These serum neutralization
titersi were similar to those seen in our previous study where llama
8 was immunized with clade A and B/C gp140 proteins and
produced the broadly neutralizing VHH J3 [26]. Thus the serum
responses seen were considered strong enough to commence
phage library construction and screening for individual VHH
using the previously described direct neutralization protocol [26].
VHH clones were initially identified as neutralizing via 384 well
robotic screening against two HIV pseudoviruses in the TZM-bl
assay (see methods and materials). Initial hits were verified by
repeated screening in the TZM-bl assay against a further three
viruses. The robotic screening was designed to identify antibodies
that neutralize tier 3 strains of HIV against which J3 is either
partially or completely inactive by testing initial hits for the ability
to neutralize these strains (Du172 and T257-31) at an early time
point during the validation process.
Three VHH called A14, B9 and B21 were identified as
neutralizing.1 tier 3 HIV pseudovirus and were subsequently
purified and IC50 values calculated against sixty one viruses from
a range of clades and circulating recombinant forms (CRF) (Table
S2 in S1 Text). Overall, B9 was the broadest neutralizing VHH,
blocking 77% of strains tested with a median 50% inhibitory
concentration (IC50) of 0.85 mg/ml (Fig. 1A). A14 neutralized
74% of strains tested, but with slightly more potency with a
median IC50 of 0.53 mg/ml (Fig. 1B). B21 neutralized 72% of
strains with a median IC50 of 0.8 mg/ml (Fig. 1C). The ability of
Table 1. Summary of llama immunizations.
Immunogens 96ZM965.01 and R2 92UG037 and CN54
Animal Llama 1 Llama 3 Llama 8 Llama 9
VHH B9, A14 B21 J3 3E3
Each llama received the indicated gp140 immunogen as described in the materials and methods and [26].
doi:10.1371/journal.ppat.1004552.t001
Author Summary
Developing a vaccine against HIV-1 is a priority, but it
remains unclear whether immunizations in humans can
elicit potent broadly neutralizing antibodies able to
prevent HIV-1 transmission. Llamas possess heavy chain
only antibodies and conventional heavy and light chain
antibodies. We previously reported the heavy chain only
antibody J3, which potently neutralizes more than 95% of
HIV strains, and was induced by immunization. Here we
immunized two further llamas and elicited three novel
broadly neutralizing heavy chain only antibodies, which
were identified by high-throughput screening. These
neutralizing llama antibodies target different areas of the
CD4-binding site of the virus, therefore breadth and
potency are increased when they are used in combination.
To gain greater understanding of how the llama immuni-
zations worked, deep sequencing of the HIV binding
region of the antibodies was performed. This revealed that
the antibodies were matured fully only in response to the
protein immunogens. Furthermore, the VHH elicited in
different animals, while sharing functional hallmarks, were
encoded by distinct sequences and thus could not have
been identified by a deep sequencing analysis alone. Our
results show that immunization can potentially induce
protective antibodies in llamas and provide a method to
more extensively evaluate immunization studies.
Evolution of Neutralizing Llama Antibodies against HIV
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these VHH to neutralize virus was compared to the previously
described VHH J3 and also to another newly identified VHH
called 3E3, which was produced in the same immunization study
as J3 but from a different llama (Table 1.). 3E3 was originally
selected from the phagemid library derived from llama 9 by phage
display via a competitive elution with soluble CD4 (sCD4) as
described previously in [31]. However, re-selection of an identical
clone by direct HIV-1 neutralization screening of the llama 9
phagemid library, as described in [26], indicated the breadth of
this VHH and led to its further characterization. 3E3 neutralizes
82% of viral strains from a slightly larger panel of seventy one
strains with a median IC50 of 0.73 mg/ml (Fig. 1D). However, the
ability of 3E3 and the three new VHH to neutralize viruses within
individual clades differs from that of J3, as reflected by the
variation in median IC50 values for each clade (Fig. 1E). J3 and
3E3 have similar median IC50 values for each clade, with the
exceptions of clade A and CRF AC where 3E3 has lower more
potent IC50 values. There is more variation for the three VHH
isolated following DNA/VLP/protein immunizations: for clade A
and CRF CD, A14 has a log lower median IC50 than J3, similarly
for clades C and CRF CD, A14 is more potent than J3, but for
CRF BC J3 is more potent on average, while for clades G, B and
CRF AG, all four VHH have similar median IC50 values. Notably
for CRF_AE, A14, B9 and B21 have IC50 values more than 100-
fold lower than J3.
New VHH bind to the CD4bs differently to J3
B9, B21 and A14 all bind in a dose-dependent manner to the
gp140 proteins used as the final immunogens (Fig. 2A,B). All three
VHH were found to bind to gp140 derived from clade B HIV
BX08 (gp140BX08), as does J3 but not to bind gp41 derived from
clade B HIV IIIB (gp41IIIB) as does the VHH 2H10 [32](Figure
S2A,B in S1 Text), thus the epitope(s) of these three VHH lie
within gp120. 3E3 bound in a dose-dependent manner to the
gp140 proteins (derived from HIV-1 strains 92UG037 and CN54)
(Fig. 2C,B) but also did not bind gp41IIIB. To further pin point
where the VHH binds, a gp120 protein derived from the YU2
strain of HIV with a CD4bs mutant unable to bind CD4 (D368R)
was used. No binding was seen in ELISA to this mutant by 3E3,
A14, B9 or B21 in comparison to the wild type YU2 gp120
(Fig. 2E). This confirmed that these VHH target the CD4bs of
HIV Env as does J3 [26].
However, In contrast to J3, 3E3 and soluble CD4, A14, B9 and
B21 all bind to an additional gp120 mutant called RSC3 [33]
(Fig. 2F). The RSC3 recombinant gp120 protein was resurfaced to
minimize recognition of non-CD4-binding site epitopes and used
to probe supernatants of individual B cells from an elite neutralizer
patient. This led to the isolation of VRC01, a mAb that neutralizes
90% of viruses tested [33]. However, neither A14, B9 nor B21 can
bind to the RSCD mutant in which residue 371 has been altered to
destroy the CD4 binding site (Fig. 2F) confirming their interaction
with RSC3 is via the CD4-binding site. Crystallographic studies
have revealed that VRC01, and related mAbs, bind to RSC3 by
virtue of their angle of approach which is rotated 45u [34] relative
to that of CD4 binding observed in a co-crystal with gp120 [35].
Structural studies are needed to assess whether these VHH bind in
a similar fashion to VRC01. However, the total serum response is
not dominated by these CD4-specific lineages as illustrated by the
unaltered serum binding titres at all time points for both llamas
against the RSC3 gp120 protein and the CD4-binding site mutant
version RSC3delta (Figure S1C in S1 Text).
Analysis of the DNA and encoded amino acid sequences of A14
and B9 revealed that the first two are clonal variants which aligned
most closely to the germ line denoted VHH Vg (T Verrips,
unpublished data) and that the sequence of B21 is highly divergent
from both and also aligns to a different germ line V gene sequence
Vu. B21, B9 and A14 belong to two distinct clonal families as
compared with the previously described anti–HIV-1 VHH
[26,31,36,37] and 3E3 (Figure S3 in S1 Text). Furthermore,
there is very limited similarity to the human germ line V gene
VH1-2*02 precursor of the VRC01-like broadly neutralizing
antibodies isolated from multiple patients. In contrast to the ability
of these VHH to bind RSC3 this argues against their being similar
to VRC01. At the nucleotide level the B9 and A14 precursor Vg
shares 69.83% identity with VH1-2*02 as while B9 and A14 are
68.84 and 68.73% identical respectively. The B21 precursor shares
45% nucleotide identity with VH1-2*02 and B21 is more
dissimilar with only 38.75% identity. The closest human V gene
to all three VHH precursors is VH3-23*04: B9 and A14 precursor
Vg shares 88.19% and 82.81% nucleotide identity with VH3-
23*04. While the mature B9 and A14 both share 85.26% V gene
identity with VH3-23*04 and 74.51% and 74.00% J gene identity
with JH5*01 respectively. The B21 precursor Vu shares 78.35%
with VH3-23*04 but B21 has a much lower identity to any human
V gene, the highest being to 81.05 to V3-66*02 and sharing
83.33% J gene identity with J4*02.
Mutation of B9 VHH improves affinity, potency and
breadth
Despite IC50 neutralization potency for some viruses as low as
0.02 mg/ml, we hypothesized that the affinity of these VHH could
be improved either by additional affinity maturation in the llama
or artificially by in vitro mutations of residues predicted to be
involved in the interaction with Env. Because there are no known
D genes for Lama glama, it has not been possible to identify a
germ line sequence corresponding to the CDR3 loop of these
antibodies, consequentially nor is it possible to calculate the
amount of affinity maturation within this canonical antibody-
antigen contact site. However, the presence of two aromatic
residues at positions 99 and 105 in both A14 and B9 suggest
potential Env contacts. Therefore, both these residues in turn were
mutated to glycine to evaluate their relative contributions to the
antibody-Env interaction. B9 F99G has a reduced ability to bind
gp120 (Fig. 3A) and also a log-fold decrease in neutralization
potency (Fig. 3B). The W105A mutation in B9 completely
removes binding and neutralization function. Thus these residues
are preferred and required for function respectively. Given the
shared ability of A14/B9 and the VRC01-like antibodies to bind
RSC3, we postulated that the structure-based insertion of an
additional aromatic residue prior to CDR2 used to improve the
affinity of the VCR01-like NIH45-46 antibody [38] could boost
the affinity of A14/B9. The co-crystal structure of NIH45-46 with
gp120 revealed that, despite extensive contacts between the two
proteins, the hydrophobic patch on gp120 that is filled by an
aromatic residue (phenylalanine 43) when CD4 is bound is not
occupied when NIH45-46 binds Env. The insertion of a
tryptophan at residue 54 in NIH45-46 resulted in improved
affinity and median potency from 0.41 mg/ml to 0.04 mg/ml and
expanded neutralization of six strains of HIV which are resistant to
the parental mAb [38]. Thus a tryptophan was inserted into B9 in
an attempt to improve its affinity for Env. Two B9 mutants were
generated as, due to a longer CDR2 loop in B9 relative to the
human antibody NIH45, it was not clear which residue in B9
corresponds with G54 in NIH45. Of these two B9 mutants, G53W
bound to gp120Bal.26 with comparable affinity to B9 in ELISA
whereas S54W bound more strongly than B9, with a higher
maximum binding level, to an equivalent level of J3 (Fig. 3A).
Evolution of Neutralizing Llama Antibodies against HIV
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Subsequently, the ability of the mutants to neutralize a
pseudovirus bearing the Bal.26 envelope used in the ELISA was
tested. In parallel to its wild type-like ability to bind gp120Bal.26,
G53W neutralized with a similar IC50 of 2 mg/ml compared to
2.2 mg/ml for wild type B9 (Fig. 3B). The other tryptophan
insertion pre-CDR2 mutant S54W instead showed increased
neutralization potency with a twenty-fold increased IC50 value
compared to wild type B9 (Fig. 3B). This shows that the increased
affinity seen in the binding studies correlated to improved
neutralization against a virus using the same Env protein. In
addition, S54W neutralized TRJO4551.58 and CH038 strains,
which are not neutralized by B9, with IC50 values of 37.3 and
32.9 mg/ml. While S54W showed more than a two-fold increase in
IC50 against an additional three clade B, two clade C and one
CRF BC strains (Du172, SS1196, WITO4160.33, DU156,
CH181.12) the mutant VHH did not result in improved potency
against the other clade B or CRF AG viruses tested (RHPA4259.7,
TR0.11, T266-60, 236-8) (Fig. 3C, Table S3 in S1 Text).
Furthermore, there was a trend for enhanced potency for S54W
in strains that were less well neutralized by to B9 (Fig. 3C).
Combining anti-CD4 VHH improves neutralization
coverage
Over the last 5 years many broad and potent neutralizing mAbs
have been identified [20,33,38,39,40,41,42,43,44] and it has been
postulated that combining these mAb could provide protection
against a wider range of strains whether by traditional passive
transfer at much lower doses than previously imagined [11] or via
novel gene transfer strategies [3]. We hypothesized that as human
mAb can be successfully combined, without detrimental effects on
their individual neutralization activities [19], A14, B9 and B21
identified in this study could also be combined with other VHH.
These three VHH were mixed with J3 and 3E3 and then assayed
for the ability to neutralize HIV in comparison to the same
concentration (10 mg/ml) of each VHH in isolation. Viruses with
differential susceptibilities to the five VHH were chosen from
clades A, B, C and CRF_AG. For all six viruses the mix of five
VHH resulted in an IC50 of improved or equivalent potency to
the most potent of the five components (Fig. 4A). Therefore, these
CD4 binding site VHH do not interfere with one another’s
function, thus we can extrapolate that the IC50 value for each
virus in the panel for the mix of five would be equivalent to that of
the most potent VHH against each particular virus (Fig. 4B). This
represents an improvement over the use of J3 alone because, while
J3 neutralizes 97% of this panel of 61 viruses, the combination
neutralizes 100%, and for some viruses the potency of J3 is
superseded by A14, B9, B21 or 3E3, resulting in a predicted
median IC50 of 0.17 mg/ml for the combined antibodies (Fig. 4C).
Affinity maturation of neutralizing VHH occurs in
response to immunizations
Whether llamas produce neutralizing conventional antibodies
against HIV in response to immunization is unknown, but it is
plausible that the narrower HCAb are more easily elicited against
recessed targets such as the CD4 binding site of HIV than
conventional antibodies. Recent data have demonstrated that the
anti-HIV potency of J3 is enhanced, when the VHH is presented
in a full-length HCAb format, therefore, the neutralization activity
of these VHH is not due to their being only the 15 kDa variable
region [45]. However, whether or not HCAb can more easily be
elicited than IgG does not alter one similarity between neutralizing
antibodies derived from HIV-positive patients and J3, namely that
their unmutated ancestors do not bind HIV Env [46,47,48],
except when modified to do exactly that [49,50,51] or in one
documented case of infection [52]. Reverting just three residues in
J3 to germ line removes all ability to bind to either immunogen
used to elicit the J3 parental HCAb [26]. Therefore, it is not clear
how the antibody was elicited and whether the immunogen
interacted with a rare naı¨ve B cell bearing the unmutated ancestor
or if the J3 B cell was only boosted by the HIV-based
immunizations having been previously affinity matured in
response to a different antigen encountered by the field-reared
llamas.
To resolve this uncertainty, deep sequencing of VHH libraries
was performed. This approach has previously provided insight into
the development of VRC01-like antibodies in multiple HIV-
positive donors [53], enabled analysis of multiple lineages with
distinct specificities arising within an individual donor [54] and
allowed in-depth analysis of the heavy chain V gene usage in Env
immunized macaques [55]. Briefly, VHH from four immunized
llamas and seven naı¨ve llamas were amplified from the phagemid
library by PCR using primers specific to the 59 and 39 conserved
regions of the VHH and subjected to 454 sequencing. Firstly, we
sequenced libraries from llamas 8 and 9 from which J3 and 3E3
were isolated respectively. Llamas 8 and 9 were both immunized
with gp140 protein derived from HIV strains 92UG037 and CN54
[26,31] (Table 1). Secondly, we sequenced libraries from llamas 1
and 3 described in this study, which produced the VHH A14, B9
and B21. Llama 1 and 3 libraries were generated at two separate
time points: after the initial three sets of VLP-DNA immunizations
and after four sequential gp140 protein boosts. In addition, seven
naı¨ve animals previously used to generate naı¨ve VHH libraries
from which antigen-specific VHH can be produced via in vitro
affinity maturation [56] were sequenced as a control for the
variation within the HCAb repertoire of the immunized llamas.
All llamas used were genetically outbred and raised outdoors in
contrast to laboratory animals often used for immunization
studies.
Two sequencing runs per VHH library were pooled resulting in
103677 to 213138 unique sequences per sample. Notably, the
clonal structure of the VHH repertoire in the naı¨ve animals
differed to that in immunized animals (Table S4 in S1 Text).
Network diagrams [57] (Figs. 5 and 6) were constructed whereby
each point represents an individual sequence Any sequences
differing by only one DNA base were connected by linkages. This
results in large clusters within a network diagram for large clonal
families and many individual points connected to only a few other
points representing sequences with fewer clonal relatives. Thus, in
a network diagram (normalized for number of sequences) with
larger clusters, there are more linkages but fewer clonal families
representing lower antibody diversity. This scenario is exemplified
by the naı¨ve llamas, whose networks had an average of 30269
linkages. In contrast, significantly fewer linkages (8843 linkages,
p = 0.001) were seen in the immunized animals and only small
Fig. 1. 3E3, A14, B9 and B21 neutralization breadth and potency. (A, B, C, D) Each spoke represents a strain of HIV neutralized by B9 (A), B21
(B) A14 (C) and 3E3 (D) in the TZM-bl assay described in the Materials and Methods. Strains from different clades and CRF are color-coded according
to the labels. The outer circle represents an IC50 of ,1 mg/ml, the inner circle ,5 mg/ml and the centre of the circle 50 mg/ml. legend. (E) Median
IC50 mg/ml generated in the TZM-bl assay for each clade/CRF shown on the X-axis for the four VHH indicated in the color-coded legend. All viruses
were assayed in duplicate to generate IC50 values.
doi:10.1371/journal.ppat.1004552.g001
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Fig. 2. A14, B9, B21 binding to HIV ENV. VHH binding to immunogens (A) clade B gp140 R2, (B) clade C gp140 96ZM651.02, (C) clade A 92UG037
gp140, (D) CRF BC CN54 gp140, (E) YU2 WT and D368R gp120, and (F) RSC3 mutant and RSC3 delta mutant gp120, was assessed by ELISA as
described in the Materials and Methods. The positive control for gp140 binding was J3 (McCoy et al. 2012) that for gp41 binding 2H10 [32]. The
positive control for both RSC3 gp120 proteins was D47 a non-neutralizing RSC3-specific VHH (L McCoy unpublished data). All binding assays were
carried out in duplicate and error bars represent standard deviation. These data are representative of at least three independent experiments.
doi:10.1371/journal.ppat.1004552.g002
Evolution of Neutralizing Llama Antibodies against HIV
PLOS Pathogens | www.plospathogens.org 6 December 2014 | Volume 10 | Issue 12 | e1004552
clusters, representing an increase in the number of different clonal
families as the VHH repertoire diversifies in response to the
immunizations (Figs. 5A,B and 6A,C). The mean number of
linkages per unique sequence was also found to be significantly
larger for naive than immunized llamas, further illustrating the
lower degree of divergence between the naive sequences (naı¨ve:
0.22, immunized: 0.052 linkages per unique sequence, p,0.005,
Student’s t-test). The same result is obtained when normalizing the
number of unique sequences by total reads per sample (naı¨ve:
0.21, immunized: 0.050 linkages per unique sequence, p,0.005,
Student’s t-test).
However, due to the high level of VHH diversity, even in the
immunized animals, it is not possible to identify clusters of clones
specifically induced by immunization within the network dia-
grams. This is in contrast to readily identifiable dominant clusters
observed in human B cell lymphoma patients [57] where one or
few clonal lineages expand massively to dominate the network
diagram. Therefore, to establish the relative frequency of
neutralizing clones within the VHH repertoire, individual
sequences were aligned to both the known neutralizing VHH
sequences and their most likely germ line V gene sequences and
the percentage identity to the neutralizing VHH plotted
(Fig. 5C,D). The percentage nucleotide divergence (100 minus
the percentage identity) from germ line and from the respective
neutralizing VHH sequence for each of the five neutralizing VHH
in each of the 13 llamas was examined. As some reads did not
Fig. 3. VHH mutation alters affinity, potency and breadth of neutralization. (A) VHH binding to clade B gp120 Bal.26 in ELISA detected by
their C-terminal Myc tag. (B) VHH neutralization of Bal.26 HIV pseudovirus in the TZM-bl assay. Mutant VHH were generated by site-directed
mutagenesis as detailed in the Materials and Methods. (C) The fold change in IC50 mg/ml values for B9 S54W relative to B9, indicating the increase
potency of the mutant are plotted on the Y-axis. The IC50 mg/ml values for B9 against each virus in the legend are plotted on the X-axis, indicating
the baseline potency of B9. All assays were carried out in duplicate and error bars represent standard deviation. These data are representative of at
least three independent experiments.
doi:10.1371/journal.ppat.1004552.g003
Evolution of Neutralizing Llama Antibodies against HIV
PLOS Pathogens | www.plospathogens.org 7 December 2014 | Volume 10 | Issue 12 | e1004552
extend to the 59 end of the V gene, percentage identity was
calculated by dividing the total identity by the length of the query
sequence. All reads however include the three complementarity
determining regions (CDR). Notably, a population of sequences
with identity to J3 greater than the germ line precursor (85.6%) is
found only in immunized llama 8 which produced the J3 HCAb
(population above the dotted line in Fig. 5C right-hand panel
compared to naı¨ve llama 3 sequences shown in left-hand panel). In
addition none of the sequences obtained from any of the naı¨ve
llamas are more closely related to J3 than the germ line (85.6%
identity) (Figure S4 in S1 Text).
For the other llama immunized in parallel (llama 9), the most
broadly neutralizing VHH was 3E3 described herein. Again, a
population of sequences with identity greater to 3E3 than its germ
line precursor Ve (which differs to that of J3) was observed only for
llama 9 (population above the dotted line in Fig. 5D right-hand
panel compared to naı¨ve llama 3 in the left-hand panel).
Interestingly, llama 9 gave rise to no sequences with greater
identity to J3 than germ line (Figure S4 in S1 Text) and llama 8
gave rise to no sequences closely related to 3E3. Therefore, the
same immunogens and immunization protocol in two different
animals gave rise to two separate clonal lineages of CD4-binding
site broadly neutralizing HCAbs. Remarkably, both lineages have
incurred a three-residue deletion in CDR2 during maturation
suggesting the immunogens imposed constraints which resulted in
a similar structural solution to high affinity binding that was
achieved by different underlying sequences.
DNA/VLP priming resulted in affinity maturation of VHH
that resulted in binding but not to a sufficient level to
enable neutralization
A limitation of the sequencing analysis of immunized llamas 8
and 9 described above is that they could be compared only to a
Fig. 4. Combined breadth and potency of anti-CD4bs VHH. (A) IC50 values in mg/ml against the HIV strains indicated in the left-hand column
on TZM-bl cells. VHH were titrated five-fold in duplicate both individually (from 10 mg/ml) and in combination with one another in the same plate for
each virus. IC50 values of less than 0.1 are color-coded in dark red, those between 0.1 and 1 in red, those between 1 and 10 in orange and those
above 10 in yellow. (B) IC50 values in mg/ml against each of the HIV strains indicated on the X-axis are shown for J3 or the combined VHH according
to the color-coded legend. (C) Each spoke represents a strain of HIV neutralized by J3 or the combined VHH. Strains from different clades and CRF are
color-coded according to the labels. The outer circle represents an IC50 of ,1 mg/ml, the inner circle ,5 mg/ml and the centre of the circle 50 mg/ml.
doi:10.1371/journal.ppat.1004552.g004
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cohort of seven naı¨ve llamas and not to a pre-immunization time
point as no samples from llamas 8 and 9 were available except
after the final immunization. In contrast, llamas 1 and 3
immunized in the protocol described herein were sampled at
two discrete time points: day 54 after the DNA/VLP immuniza-
tions and day 174 after four subsequent gp140 boosts. Serum
samples from day 54 showed binding but no detectable
neutralization activity (Figure S1 in S1 Text). In contrast, the
serum samples from day 174 neutralized pseudoviruses from
subtypes A, B and C and the neutralizing VHH A14, B9 and B21
were isolated from the phage library generated from lymphocytes
obtained at day 174. VHH Networks showed no change in
sequence interconnectivity between the two time points in either
llama, and both time points showed a higher degree of
immunefocusing on the encountered antigen as represented by a
lower average number of network linkages as compared to the
naı¨ve llamas (Figs. 5A, B and 6A, C). Sequences from both time
points were analysed to understand whether clones related to A14,
B9 and B21 arose during the initial DNA/VLP immunization
cycle at levels too low to result in sera neutralization and were then
boosted by the protein immunizations or whether the protein
alone was the antigen responsible for their affinity maturation
(Fig. 6B and D). As seen for llamas 8 and 9, a population of
sequences sharing a higher identity with the neutralizing VHH B9
or B21 than their germ lines was seen in both llamas after the
protein immunizations at t = 174. However, no sequences from
t = 54 in either llama had greater identity with the affinity matured
VHH than the relevant germ line as indicated by the horizontal
dotted line on each plot. The same pattern was seen when the
closely related A14 VHH was used in place of B9 to analyse the
sequences generated from llama 1 and both time points. Thus
affinity maturation to a level that produced neutralizing activity
was not achieved during DNA/VLP priming phase of the
immunizations.
Reverting V gene to germ line does not prevent B9, A14
and B21 function
Despite representing two separate neutralizing lineages derived
from two animals (Table 1) J3 and 3E3 have both incurred a
three-residue deletion in CDR2 during maturation and the
reversion of this mutation abrogates J3 function [26]. Similarly,
re-insertion of the three germ line residues into 3E3 removed its
ability to bind gp140 (Figure S2 in S1 Text). This suggests the
immunogens imposed constraints resulting in a common structural
mode of high affinity encoded by different sequences. To gain
insight into which mutations incurred during affinity maturation
were responsible for the A14, B9 and B21 function, germ line
reverted VHH (GL VHH) were recombinantly produced. These
comprised the relevant germ line V gene paired with the mature
CDR3 and J sequence of each VHH (Figure S3 in S1 Text). Both
GL B9 and A14 showed measurable binding to the R2 gp140
immunogen by ELISA, which was weaker than that seen for the
unreverted VHH (Fig. 2A,B), but no binding to 96ZM651.20
gp140 (Fig. 7A,B). Thus the key mutation events required for Env
binding are within the CDR3, which in the GL VHH is the same
as in the matured VHH. GL B21 on the other hand bound to both
immunogens (Fig. 7A,B) although to a lesser degree than B21
(Fig. 2A,B) which has additional mutations within the V gene. A
similar pattern of neutralization activity for the GL VHH was
seen, with GL B9 and A14 neutralizing R2 only and GL B21
neutralizing both autologous viruses (Fig. 7C,D) although in all
cases the neutralization by the GL VHH was less potent than by
the mature VHH. This raised the question of whether these GL
VHH, which have a mature CDR3, occurred in the llamas prior
to immunization or at t = 54 in addition to at t = 174 when the
phagemid library from which the VHH were isolated was
generated. Although no neutralization activity was observed at
t = 54 it is theoretically possible these VHH could be present but at
extremely low frequencies which would not result in neutralizing
sera. However, as described above no sequences with greater
identity to the affinity matured VHH than germ line were
identified at t = 54 (Fig. 6). To further examine whether any clones
similar to the GL VHH produced recombinantly were present at
t = 54 additional analysis of the sequencing data was performed.
Sequences were filtered into subsets, which shared V gene usage
with each VHH. The CDR3 sequences of the subsets were then
analyzed for the frequencies of residues that matched to those
found in the mature CDR3 at the same position and the number
of unique reads where sequential CDR3 residues (runs) matched to
the mature CDR3 sequence. Total frequencies of matching
residues at individual CDR3 positions did not vary substantially
between time points for any of the VHH in each llama (Fig. 7E).
However, no unique sequences were found at t = 54 which
matched the mature CDR3 for more than the initial 5,1, or 3
CDR3 residues for B9, A14 and B21 respectively (Fig. 7F,G,H)
following the CAR/CNA residues found at the end of each V
gene. In contrast multiple copies of sequences with fully matching
CDR3s were found for all VHH in the t = 174 subsets. Thus the
GL VHH tested in this study which both bind the R2 immunogen
and neutralize the corresponding virus were not present at t = 54
at detectable level by 454 sequencing and it is therefore likely that
they were absent or extremely rare at t = 0.
Discussion
This study has demonstrated that broadly HIV neutralizing
llama HCAb can be reproducibly elicited by immunization
(Fig. 1). Despite diverse immunization protocols, the best HCAb
isolated by direct screening of VHH for neutralization breadth all
target the CD4-binding site of HIV Env (Fig. 2) and those in most
recent immunization study can bind to the CD4-binding site
focusing gp120 mutant RSC3. Notably, the serum binding titres
for RSC3 and RSC3delta are highly comparable and thus the sera
Fig. 5. VHH repertoires of naı¨ve and protein-immunized llamas. VHH sequences from immunized llamas 8 and 9 and seven naı¨ve llamas were
amplified from their respective phagemid libraries by PCR using primers specific to the 59 and 39 conserved regions of the VHH and subjected to 454
sequencing. (A) Unique sequences generated from the indicated llama phage library were used to build end-joining network diagrams with
significantly more linkages (P = 0.001) in the naive llamas versus (B) immunized llamas. (C) Shared percentage identities with neutralizing VHH J3 and
divergence from its inferred V gene Vt were calculated for all unique sequences from the control naı¨ve llamas, and the J3-source llama 8. The left
hand panel shows percentage identity for all sequences from naı¨ve 3 plotted against divergence from Vt. The right panel shows percentage identity
for all sequences from llama 8 plotted against divergence from Vt. The horizontal dotted line on each panel indicates the percentage identity shared
by Vt and J3 and the vertical dotted line indicates the divergence of J3 from Vt, (D) Shared percentage identities with neutralizing VHH 3E3 and
divergence from its inferred V gene Ve were calculated for all unique sequences from the control naı¨ve llamas, and the 3E3-source llama 9. The left
hand panel shows percentage identity for all sequences from naı¨ve 3 plotted against divergence from Ve. The right panel shows percentage identity
for all sequences from llama 9 plotted against divergence from Ve. The horizontal dotted line on each panel indicates the percentage identity shared
by Ve and 3E3 and the vertical dotted line indicated the divergence of 3E3 from Ve.
doi:10.1371/journal.ppat.1004552.g005
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responses of these llamas are not dominated by RSC3-specific
anti-CD4-binding site clones, and the neutralizing VHH described
herein are minority variants of the total response, in agreement
with the weak neutralization titres observed (Figure S1 in S1 Text)
and the low overall frequency of sequences belonging to these
lineages (Fig. 6). It may be that only CD4-binding site specific
lineages were isolated due to easier elicitation of such specificities
due to the site’s conservation within the unstabilised gp140 protein
immunogens used (unlike trimer-specific epitopes) or due to the
preference of the single-headed HCAbs for long CDR3 protru-
sions which can effectively bind into recessed canyons such as the
CD4-binding site. It must also be noted that only one broadly
neutralizing lineage in each animal was identified from 5000
clones and other specificities may have been found by screening
more clones. In addition, although the screening was performed
on phagemid libraries derived from llama PBMCs using primers
designed to amplify all known VHH families (T Verrips,
unpublished data) bias may have been introduced by this process
if certain sequences were less preferentially incorporated in to the
library. Similarly, some VHH may not have been well expressed in
the bacterial system, preventing them from being identified by the
robotic screening.
Interestingly the fine specificities of CD4 binding vary between
clones resulting in the ability of each clonal lineage of VHH to
effectively neutralize some strains of HIV which are resistant to the
other VHH (Fig. 1). A14, B9 and B21 are highly potent against
representatives from HIV strains circulating in certain geograph-
ical areas that J3 does not target as efficiently. We have
demonstrated that combining five of these VHH results in
superior neutralization breadth compared to that of any of the
VHH used in isolation (Fig. 4). This concurs with studies of
human antibodies targeting independent epitopes [19]. However,
all five VHH target the CD4 binding site, nevertheless, they can be
used in combination to result in neutralization potency equivalent
that of to the most potent VHH. This suggests the differences in
affinity of each VHH for any particular virus are great enough to
prevent the less potent VHH occupying the CD4 binding site
resulting in less potent neutralization. That VHH elicited by
immunizations which target the same site on Env can be used in
combination without compromising neutralization potency is
encouraging for vaccine design studies. It indicates that the co-
induction of a variety of antibodies targeting the same site is not
detrimental to neutralization function in itself, although how this
can be achieved by immunization remains to be determined. Since
the combination of these five anti-CD4 binding site VHH
neutralized 100% of strains tested with an IC50 of less than
0.2 mg/ml (Fig. 4), their combined use in a topical anti-HIV
microbicide [28] could provide a higher barrier to infection and
viral escape than the use of any one VHH individually. It has
previously been shown that virus escape occurs from passively
transferred human antibodies used to treat infection when three or
less are used in combination whereas no escape was seen from a
combination of five antibodies [58]. How significant escape would
be in the setting of chronic microbicide use remains to be
determined but the use of multiple VHH targeting the same site in
different ways should reduce the risk and provide a higher barrier
to transmission.
We have also shown that the VHH described can be improved
in terms of potency and breadth via site-directed mutagenesis. The
residues altered were selected based on the observation that the
three VHH described herein, B9, A14 and B21, bind to the RSC3
probe that was used to isolate the VRC01-class of human CD4
binding site broadly neutralizing antibodies (Fig. 2) and that
previously the introduction of an aromatic residue into the
VRC01-like antibody NIH45-46 resulted in increased breadth and
potency [38]. The introduction of an aromatic in the mutant
B9S54W also resulted in increased potency and breadth (Fig. 3)
despite the lack of significant sequence homology between
VRC01-like antibodies and B9, A14 and B21 (compounded by
the lack of a light chain which contributes to the VRC01-Env
interface). Thus, it cannot be concluded that these VHH are
VRC01-like or that these immunogens can elicit such antibodies in
humans. It would be of interest to undertake structural studies to
establish whether there are any structural similarities.
While the overall frequency of A14, B9 and B21-like sequences
is low there is a clear expansion of these lineages after the animals
received four gp140 protein boosts (Fig. 6). This low frequency
agrees with the weak neutralization breadth seen for the t = 174
serum samples (Figure S1 in S1 Text). In contrast, the deep
sequencing analysis of VHH present at t = 54 shows no over-
representation of the sequences which share higher levels of
identity with the neutralizing VHH than the germ line (Fig. 6).
This suggests that the low-level maturation achieved during the
DNA/VLP immunizations was not sufficient for neutralization or
the definition of these clonal lineages. Interestingly, A14, B9 and
B21 GL VHH (with the V gene reverted to germ line but mature
DJ regions) were all able to bind the R2 immunogen and
neutralize the homologous virus (Fig. 7) but only B21 GL could
bind the both immunogens and neutralize both viruses. This
difference in binding ability to the two immunogens suggests the
R2 immunogen may have driven the earlier stages of affinity
maturation of this lineage in llama 1, which resulted in clones that
could also recognize 96ZM651.02 gp140 as the immune response
progressed and the lineage developed breadth via mutations in the
V gene region. That these germ line reverted VHH could bind
and neutralize at first appears to contradict the lack of
neutralization activity and the inability to identify clones belonging
to each lineage at t = 54. However, further sequencing analysis
established that these germ line chimera were not present at the
earlier time point, as no sequences with the fully mature DJ
regions paired to the relevant germ line V genes were detected at
t = 54 whereas between 50 and 250 copies of such clones were
present at t = 174. Thus we can conclude that mutations occurred
in the CDR3s during the protein immunization phase resulting in
Fig. 6. VHH repertoires post DNA/VLP priming and gp140 boosts. VHH sequences from immunized llama 1 at both t = 54 and t = 174 were
amplified from their respective phagemid libraries by PCR using primers specific to the 59 and 39 conserved regions of the VHH and subjected to 454
sequencing. (A) Unique sequences generated from the llama 1 were used to build end-joining network diagrams with no significant difference in the
number of network linkages between time points (B) Shared percentage identities with neutralizing VHH B9 its inferred V genes Vg were calculated
for all unique sequences from both time points. Percentage identity with B9 for all sequences are plotted against divergence from Vg for t = 54 in the
left hand panel and t = 174 in the right hand panel. (C) Unique sequences generated from the llama 3 were used to build end-joining network
diagrams with no significant difference in the number of network linkages between time points (D). Shared percentage identities between
neutralizing VHH B21 and its inferred V genes Vu were calculated for all unique sequences from both time points. Percentage identity with B21 for all
sequences is plotted against divergence from Vu for t = 54 in the left hand panel and t = 174 in the right hand panel. In both (B) and (D) the horizontal
dotted line on each panel indicates the percentage identity shared by the mature and germ line VHH and the vertical dotted line indicates the
divergence of the mature VHH from its putative germ line precursor.
doi:10.1371/journal.ppat.1004552.g006
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Fig. 7. Anti-HIV activity of germ line V gene VHH. GL VHH comprising inferred germ line V gene paired with the mature VHH CDR3 and J region
were produced. GL VHH binding to (A) clade B immunogen R2 gp140 and (B) clade C immunogen 96ZM9651.02 gp140 was assessed by ELISA as per
the materials and methods. GL VHH neutralization of (C) R2 pseudovirus and (D) 96ZM651.02 pseudovirus was assessed in TZMbl assay as per the
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neutralization ability, alongside additional mutations in the V gene
which are required for breadth at least in the A14/B9 lineage. The
germ line chimeras do however demonstrate that these VHH
require only mutations within their CDR3 for neutralization
activity. This is in agreement with the finding that the F99G and
W105G substitutions in the CDR3 of B9 diminish and destroy its
anti-HIV activity respectively (Fig. 3A,B). This is in contrast with
the fact that J3 and 3E3 require a deletion within the V gene
which shortens the CDR2 loop by 3 residues [26], (Figure S2 in S1
Text) to bind and neutralize HIV Env.
Notably, the global incidence of A14, B9 and B21-like
sequences is low within even the t = 174, however this is across
total VHH from whole peripheral blood, not just those specific for
these immunogens because no panning enrichment was performed
with the phagemid library prior to neutralization screening. This
greatly increases the signal-to-noise ratio in the deep sequencing
analysis and thus it is not possible to identify which clones are
immunogen-specific and analyse these as a subset. This is because
a primary sequence alone does not allow us to predict function
unless the sequence is highly similar to a characterized clone.
Therefore, future studies should involve an immunogen-specific
flow cytometry selection of the immungen-specific llama B cells
prior to generating the library to more easily identify clusters of
immunogen-specific VHH. Such studies may also provide insight
into whether the high level of divergence from germ line (relative
to human immunization studies) seen in these clones is standard in
the HCAb response to immunization. That HCAb memory B cells
may be more mutated from germ line relative to conventional IgG
B cells is not entirely unanticipated. Naı¨ve HCAbs inherently start
from a less diverse paratope repertoire as they do not combine a
heavy and light chain, both derived from VDJ recombination.
Therefore, in order to successfully advance through successive
rounds of affinity maturation and compete for immunogen with
the conventional antibodies, llamas also produce (estimated at
70% of total IgG) the HCAbs that may undergo additional
mutations. In addition, the mutation process is inherently random,
and deleterious (stop codons etc.). In a normal B cell a deleterious
mutation in either chain will prevent expansion of that lineage,
whereas in a HCAb B cell a successful heavy chain does not
require a functioning light chain to proceed.
It is significant that parallel immunization of llamas 8 and 9
gave rise to two separate clonal lineages of CD4 binding site
broadly neutralizing HCAbs which have both incurred a three
residue deletion in CDR2 during maturation. This finding
indicates that the immunogens imposed constraints, which resulted
in a similar structural solution to high affinity binding achieved by
different sequences. This has implications for the use of deep
sequencing analysis of immunization studies: if the sequence of J3
had been used as a reference to filter the sequences from llama 9
(without prior screening of VHH from llama 9), no J3-like
antibodies would have been found, 3E3 would not have been
identified and it would have falsely appeared that the immuniza-
tion of llama 9 had failed. These findings are consistent with the
observation that HIV Env immunization activates a highly
polyclonal B cell response of substantial genetic diversity in NHP
[55]. This is in contrast to the well-characterized VRC01-like
family of CD4-binding site antibodies identified in multiple HIV-
positive donors, which share both a heavy chain V gene precursor
and unusual features at a DNA sequence level which could allow
sequencing-based identification of other similar antibodies in
distinct patients [53]. Thus, this study has implications for analysis
of human vaccine studies, as in addition to searching for defined
lineages it is worthwhile to perform functional analysis of
monoclonal antibodies that may have found new structural
solutions to high affinity binding which cannot be discerned from
DNA sequence alone.
A critical implication of this work for the field of HIV vaccine
design is the observation that the most potent and broad individual
anti-HIV VHH, J3, was elicited in response to the gp140
immunogens used. It has been suggested that the extensive affinity
maturation of antibodies and HCAbs which neutralize HIV could
be the result of prior affinity maturation of clones to a non-HIV
antigen. Hypothetically, such a B cell clonal lineage could have a
greater affinity for Env than any germ line B cell and could either
be boosted or further affinity matured in response to Env
immunization. Deep sequencing analysis has shown that this is
highly unlikely in the case of J3 as no sequences were generated by
deep sequencing of the seven naı¨ve llamas or three other
immunized llamas that share greater identity with J3 than its
putative germ line V gene. Paradoxically, it remains the case that
even minimal mutation towards the J3 germ line V gene abolishes
the ability to bind either immunogen used [26]; the reintroduction
of the three germ line CDR2 residues renders the VHH incapable
of binding Env. However, it must be noted that the llama
immunization model is not only an animal model but one resulting
in a subtype of antibodies not produced in humans. Furthermore,
the neutralizing HCAb induced occurs in the llamas at a low
frequency that does not result in broadly neutralizing sera, the goal
for a protective HIV vaccine. However, this model has allowed us
to examine four HIV broadly neutralizing clonal lineages induced
by vaccination, which has not been possible in other animal
models to date, and highlights the many challenges of evaluating
immunization studies with deep sequencing of antibody variable
regions.
Materials and Methods
Ethics statement
This study was performed in strict accordance with the Dutch
Experiments on Animals Act 1997. In accordance with article 18
of the Act, the protocol was assessed and approved by the Animal
Ethics Committee of Utrecht University (permit number:
DEC#2007.III.01.013). All efforts were made to minimize
discomfort related to immunizations and blood sampling. The
animal welfare officers of Utrecht University checked the
mandatory administration and supervised the proper conduct of
procedures and the well-being of the llamas that were used.
Immunization of L. glama and construction of the VHH
phage library
Llamas 1 and 3 were immunized via intramuscular injection of
plasmid DNA encoding R2 and 96ZM gp160 in PBS (7.5 mg of
materials and methods. (E) Unique sequences from llamas 1 and 3 at both timepoints were filtered for B9, A14 and B21 germ line V gene usage (Vg
and Vu) respectively. The y-axis shows the percentage of sequences within each subset with identical residues to each VHH at each individual CDR3
position (and the preceeding three V gene residues 21,22,23 = CAT/CNA) indicated on the x-axis. (F, G, H) The number of unique sequences within
the subsets which share exact runs of CDR3 residues are plotted on the y-axis against runs of increasing CDR3 length on the x-axis for (F) B9, (G) A14
and (H) B21 at the time points indicated in the legend.
doi:10.1371/journal.ppat.1004552.g007
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DNA) with or without virus like particles bearing R2 and 96ZM
envelope proteins in PBS (protein content 50 mg). Subsequently
additional immunizations were administered with intramuscular
injection of ZM96 & R2 gp140 protein (50 mg each) in a freshly
prepared 4.5-ml water in oil emulsion prepared by vigorously
mixing 2 volumes of antigen with 2.5 volumes of the adjuvant
Stimune (CEDI Diagnostics). Immunizations and VHH library
construction were performed as described previously (De Haard et
al., 2005). In brief, the llamas received one dose of DNA alone,
then two doses of DNA combined with VLP, followed by four
doses of protein in adjuvant as per Table S1 in S1 Text. The anti-
Env immune response in sera was verified via neutralization of
three viruses in TZM-bl cells (Figure S1 in S1 Text). Total RNA
was isolated from between 120 and 150 million peripheral blood
lymphocytes (PBMC) collected after immunization (on day 54 and
174) and cDNA was prepared. The VHH repertoire was amplified
and cloned into the pCAD50 phagemid vector. To obtain
recombinant bacteriophages expressing the VHH as fusion
proteins with the M13 bacteriophage gene III product, trans-
formed TG1 E. coli cells were grown to logarithmic phase and
then infected with helper phage M13KO7. The phage particles
were precipitated with polyethylene glycol.
VLP and DNA immunogens
Codon optimized and c-terminal truncated (aa714–856, HXB2
numbering) R2 and 96ZM651 gp145 genes were synthesized
(GeneArt) and cloned into pcDNA3.1 using NheI and PmeI
restriction sites and NheI and XhoI respectively. DNA for
immunizations was prepared using the Qiagen EndoFree Plasmid
Giga Kit according to the manufacturer’s instructions. A Giga-
prep was performed to obtain at least 60 mg of DNA. 200 mg of
R2 virus like particles (VLPs) and 200 mg of 96ZM VLPs were
made. Pseudotyped VLPs for immunization purposes were
produced in 293F cells by transient transfected with a codon-
optimized, Rev-independent gene for Gag(IIIB) [59] and the
respective envelope encoding plasmid in a ratio of 2:1. VLPs were
harvested 72 h post-transfection, cleared by centrifugation at
3000 g for 15 min, loaded onto a 30% sucrose in PBS cushion
(5 ml for 30 ml of supernatant) and ultra-centrifuged at 100,000 g
for 2 h. The pellet was resuspended overnight in PBS and stored at
280uC. For the quantification of incorporated envelope protein
an ELISA was used. Each subsequent ELISA washing step was
carried out with 200 ml PBS+0.05% Tween20 and each incuba-
tion was done for one hour at room temperature. A Clear 96-well
MaxiSorp plates (NUNC) were coated overnight with 1 mg/ml of
antibody 5F3 (Polymun). Plates were blocked using 10% fetal calf
sera in PBS+0.05% Tween20 followed by three washings.
Pseudotyped VLPs were denatured in the presence of 0.5%
Triton-X for 1 h and the VLPs as well as recombinant gp140
standard protein were added in serial dilution followed by
incubation. After three additional washing steps 50 ml of a
1:1000 dilution of antibody MH23 (NIBSC) was added and
incubated. The plate was washed three times before adding
0.65 mg/ml anti-mouse horseradish peroxidase–conjugated Ab
(Dako) followed by incubation. After six washes TMB ELISA
substrate was added, and the plates were incubated until standard
proteins were visible. Purified gp140 from R2 and from 96ZM
were mixed with Stimune commercially available Stimune
adjuvant (CEDI Diagnostics, Lelystad, The Netherlands).
Recombinant HIV-1 Env proteins
Recombinant trimeric gp140 from HIV-1 92UG037 (clade A)
for ELISAs was provided by S. Jeffs (Imperial College London,
London, England, UK). Recombinant D368R and wild-type
monomeric gp120 from HIV-1 YU2 (clade B) and recombinant
RSC3 and RSC3D37 for ELISAs were provided by J. Mascola
(National Institutes of Health [NIH], Bethesda, MD). Recombi-
nant gp41 from HIV-1 IIIB, recombinant trimeric gp140 from
HIV-1 CN54 and BX08 were obtained from the CFAR, NIBSC
and were donated by Immunodiagnostics and Polymun Scientific,
respectively.
Cells
TZM-bl cells (Derdeyn et al., 2000; Wei et al., 2002; Li et al.,
2005) were obtained through the NIH AIDS Research and
Reference Reagent Program from J.C. Kappes (University of
Alabama at Birmingham, Birmingham, AL), X. Wu (NIAID,
NIH), and Tranzyme, Inc. and cultured in Dulbecco’s modified
Eagle medium (Invitrogen) containing 10% (vol/vol) FCS.
Viruses
Pseudoviruses were generated from two separate plasmids, one
encoding a full length HIV virus with a defective env and the other
encoding a functional env. This results in non-replication
competent HIV progeny viruses that undergo only one cycle of
infection, which is sufficient to test the ability of an antibody to
inhibit HIV entry into cells. HIV-1 IIIB was propagated in H9
cells all other replication-competent virus stocks were prepared
from HIV-1 molecular clones by transfection of 293T cells. HIV-1
IIIB (ARP101) was obtained from the CFAR, NIBSC. IIIB was
donated by R. Gallo and M. Popovic (University of Maryland
School of Medicine, Baltimore, MD). HIV-1 Env pseudotyped
viruses were produced in 293T cells by co-transfection with the
pSG3Denv plasmid (Kirchherr et al., 2007). The subtype B and C
HIV-1 Reference Panels of Env Clones (Li et al., 2005, 2006) were
obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, National Institute of Allergy
and Infectious Diseases (NIAID), NIH. HIV-1 subtype
CRF07_BC Gp160 clones, subtype CRF02_AG Gp160 clones
(263-8, T278-50, and T266-60), and the 92UG037, 93MW965.26,
and 96ZM651.02 Gp160 clones were provided by D. Montefiori
(Duke University Medical Center, Durham, NC) through the
Comprehensive Antibody Vaccine Immune Monitoring Consor-
tium (CA2 VIMC) as part of the CAVD. All additional
pseudoviruses were produced at the CAVD Preclinical Neutral-
izing Antibody Core laboratory.
Serum neutralization
Serum samples were heat-inactivated to destroy complement by
incubation at 56uC for 1 h before use in neutralization assays.
Threefold serial dilutions of llama sera were then tested, starting at
a 1:5 dilution in the 96-well plate the TZM-bl cell-based assay
developed by Derdeyn et al. (2000), Wei et al. (2002), and Li et al.
(2005), with Bright-Glo luciferase reagent (Promega) using a
Pherastar plate reader (BMG Labtech).
Isolation of anti–HIV-1 VHH through robotic direct HIV-1
neutralization screening
Phages expressing the cloned VHH repertoire were plated onto
agar containing 100 mg/ml ampicillin and 2% syncytial stain (1 g
methylene blue and 0.33 g basic fuchsin in 200 ml methanol).
Individual clones were picked using a Norgren CP7200 colony
picker (RapidPick; Hudson Robotics) into 384-well master plates.
6144 individual clones were expressed in TG1 E. coli cells in a
384-well plate format. Each clone was expressed in 150 ml of 26
TY medium containing 100 mg/ml ampicillin and 0.1% glucose,
followed by induction of VHH production with 0.1 mM isopropyl-
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b-dthiogalactopyranoside. Bacterial pellets were frozen at -80uC
for a minimum of 1 h and then thawed and resuspended in PBS.
The periplasmic extract from each well was separated from
bacterial debris by filtration through a 0.45-mM polyvinylidene
fluoride membrane and screened for the ability to neutralize HIV-
1. To enable high-throughput screening and characterization of
VHH, neutralization was measured using 50 50% tissue culture
infective doses of virus in a 384-well plate adaption of the 96-well
plate the TZM-bl cell-based assay developed by Derdeyn et al.
(2000), Wei et al. (2002), and Li et al. (2005), with Bright-Glo
luciferase reagent (Promega) using a Pherastar plate reader (BMG
Labtech). DNA from the individual VHH that neutralized any tier
2/3 viruses to ,20% seen with control was purified, sequenced,
and recloned into the pCAD51 expression vector followed by
transformation into TG1 cells for purification and further
characterization.
VHH purification and neutralization characterization
Expression from the pCAD51 vector incorporates a 6-His and a
c-Myc tag to the C terminus of the VHH and removes the
bacteriophage gene III product. The VHH were purified by
means of the attached His tag using TALON Metal Affinity Resin
(Takara Bio Inc.). Mutagenesis of VHH DNA was achieved using
the QuikChange site-directed mutagenesis kit (Agilent Technolo-
gies) according to the manufacturer’s instructions. Mutant VHH
protein was expressed and purified as described above. The
neutralization activity of the VHH was assayed in duplicate/
triplicate at either University College London or VIMC labora-
tories. No virus inactivation was observed with a negative control
VHH with no specificity for HIV was used as control (De Haard et
al. 2005). or with a pseudovirus bearing a mouse leukemia virus
Env. VHH IC50 titers were calculated using the XLFit4 software
(IDBS) or the Labkey Neutralizing Antibody Tool (Piehler et al.,
2011). Cran R radial plots were used to display the inverse IC50
values (Fig. 1).
ELISAs
Clear 96-well MaxiSorp plates (Thermo Fisher Scientific) were
coated overnight with 2 mg/ml of recombinant Env. Plates were
blocked using 5% milk powder in TBS. Serial dilutions in TBS
supplemented with 0.05% Tween (TBS-T) containing 1% milk
powder (TMT) of the VHH to be assayed and of a negative
control VHH were then added to the plates in triplicate wells, and
the plates were incubated at room temperature for 1 h and
subsequently washed four times with TBS-T. The wells were then
incubated with 0.5 mg/ml mouse anti–c-Myc–horseradish perox-
idase–conjugated Ab (Roche) in TMT for 1 h at room temper-
ature. After six washes with TBS-T, TMB ELISA substrate
(Thermo Fisher Scientific) was added, and the plates were
incubated at 37uC for 0.5 h. Absorbance at 450 nm was detected,
and background-subtracted data were plotted against VHH
concentration.
Sequencing
Two technical replicates were run for each sample and the
corresponding sequence datasets were merged. Any reads that
were identical sub-sequences of other reads were removed and the
read count for the longer sequences adjusted accordingly. Raw
MiSeq reads were filtered for base quality (median.32) using the
QUASR program (http://sourceforge.net/projects/quasr/).
Overlap between forward and reverse reads, where no nucleotide
mismatches are allowed. MiSeq forward and reverse reads were
merged together if they contained identical overlapping region
of.65 bp, or otherwise discarded. No nucleotide mismatches are
allowed in the overlap regions, as this would be indicative of
sequencing error or recombination. Primer sequences were
trimmed from the reads, and sequences retained for analysis only
if both primer sequences were identified with 100% match. Non-
immunoglobulin sequences were removed and only reads with
significant similarity to reference Llama IgHV and IgHJ genes
using BLAST (Altschul et al., 1990) were retained (10-10, 10-3 e-
value threshold respectively due to differences in gene length).
Reads were retained if they contained complete open reading
frames (without stop codons). Non-functional BCRs, PCR error or
recombination may lead to the artificial introduction of stop
codons. Length filter: between 150 and 320 nucleotides. If
recombination was to occur, this filter would remove reads that
had significant changes in their length. Graphs for each sample
were generated using the igraph R library [60] with nodes
corresponding to individual read sequences and linkages between
nodes whose sequences differed by at most one nucleotide. Node
sizes were proportional to the number of observed reads for each
sequence. Sequence similarities were calculated by performing
BLASTX [61] searches on read sequences against a database of
known V gene products and reference sequences (J3, 3E3, A14, B9
and B21), counting insertions and deletions in the alignments as
non-identical residues. Divergence was calculated as (100 –
percentage sequence similarity). Divergence plots were generated
using the ggplot2 R library [62]. Custom Perl and R scripts were
used throughout to parse and analyse the sequence datasets (R
Development Core Team, 2008 http://www.R-project.org).
Supporting Information
S1 Text Table S1: Immunization Schedule. Llamas 1 and
3 were immunized via intramuscular injection as indicated in the
table. Protein injections were in a freshly prepared 4.5-ml water in
oil emulsion prepared by vigorously mixing 2 vol U of antigen with
2.5 vol U of the adjuvant Stimune (CEDI Diagnostics); Table S2:
IC50 against 77 viruses. VHH were titrated threefold from
50 mg/ml and incubated with the indicated pseudoviruses on
TZM-bl assay as described in the materials and methods. No virus
inactivation was observed with a negative control VHH or with a
pseudovirus bearing a mouse leukemia virus Env. VHH IC50
titers were calculated using the XLFit4 software (IDBS) or the
Labkey Neutralizing Antibody Tool (Piehler et al., 2011). Potent
neutralization (IC50,1 mg/ml) is color-coded red, intermediate
neutralization (1–10 mg/ml) is color-coded yellow and weak
neutralization (10–50 mg/ml) is color-coded green, non neutrali-
zation (.50 mg/ml) is colour-coded white, strains that weren’t
tested for particular VHH are indicated by a black dot; Table S3.
IC50 values for B9 VHH and S54W mutant against nine
viruses. The S54W mutant was generated by site-directed
mutagenesis as described in the materials and methods. VHH
were titrated threefold from 50 mg/ml and incubated with the
indicated pseudoviruses on TZM-bl assay. VHH IC50 titers were
calculated using the XLFit4 software (IDBS). Highly potent
neutralization (IC50 ,0.1 mg/ml) is color-coded dark red, potent
neutralization (0.1–1 mg/ml) is color-coded red, intermediate
neutralization (1–10 mg/ml) is color-coded yellow, weak neutral-
ization (10–50 mg/ml) is color-coded green; Table S4: Statisti-
cal analysis of sequence variation between immunized
and naı¨ve llamas. The mean cluster size was found to be
significantly larger for naive than immunized llamas. When
considering only non-singleton clusters (i.e. clusters of sequences
with 2 or more members) the average cluster size was also
considerably larger for the naive llamas. The mean number of
reads per unique sequence was also higher in the naive compared
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to the immunized samples highlighting the greater sequence
diversity in the immunized samples. This was despite the total
number of reads not varying significantly between either set of
samples and further reinforced by the immunized animals
generating significantly higher numbers of unique sequences per
sample; Figure S1: Post-immune sera anti-HIV activity.
(A) Threefold serial dilutions of llama sera were tested against the
indicated pseudoviruses, starting at a 1:5 dilution in the 96-well
plate the TZM-bl cell-based assay as described in the materials
and methods. (B) Threefold serial dilutions of llama sera were
tested against the indicated immunogens, starting at a 1:20
dilution. Binding was detected with HRP-conujugated anti-llama
antibody. Serum samples were heat-inactivated to destroy
complement by incubation at 56uC for 1 h before use; Figure
S2: VHH binding to HIV Env proteins. VHH binding to (A)
clade B gp140 BX08, (B) clade B gp41 IIIB and (C) clade A gp140
92UG037 was assessed by ELISA as described in the Materials
and Methods. The positive control for gp140 binding was J3 [26]
and that for gp41 binding 2H10 [32]; Figure S3. VHH
sequence alignments. Alignment of A14, B9, B21, 3E3, their
germ line V genes and human V gene VH3-23*04 and VH1-2*02;
Figure S4. Shared sequence identity with J3 relative to
divergence from germ line for all naı¨ve and immunized
llamas. Shared percentage identities with neutralizing VHH J3
and divergence from its inferred V gene Vt were calculated for all
unique sequences from the seven control naı¨ve llamas, and the
four immunized llama including the J3-source llama 8. Each panel
shows percentage identity for all sequences from the indicated
llama plotted against divergence from Vt.
(PDF)
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